ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the ...
Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow enhancements. JENA, (Germany), SHANGHAI, (China), | 27 ...
The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without ...
Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /PRNewswire/ ...
Aligne Wealth Advisors Investment Management (AWAIM) proactively manages risk and return opportunities as markets evolve. This forward-looking approach recently led to strategic portfolio adjustments ...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included ...
Nevertheless, we were able to post slight growth thanks to the DORC acquisition. The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market ...
The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market and the general recovery in order entry and order backlog give us ...
Customers are waiting for the new Kinevo 900S, which became available in the US and Europe in late 2024, and Visumax 800, which was recently approved in China and should be available for purchase ...
Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.
Shares of Carl Zeiss Meditec AG (ETR:AFX) dropped 6% today after the company reported its first-quarter revenues, which showed a slight increase of 1.2% versus the Vara consensus but were coupled with ...
Hosted on MSN19d
Goldman Sachs lifts Carl Zeiss Meditec stock to NeutralFelton's outlook is somewhat buoyed by the recent approval of Visumax 800 in China, which occurred earlier than anticipated. This development could potentially mitigate further downside risks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results